Jakarta, CNBC Indonesia – The share prices of two listed subsidiary companies of PT Bio Farma (Persero), namely PT Kimia Farma Tbk (KAEF) and PT Indofarma Tbk (INAF) slightly strengthened in the first trading session, Tuesday (11/8/2020) amid the increase in the Composite Stock Price Index. (JCI) of 5,191.
IDX data noted that KAEF’s shares rose 1.50% at the level of Rp 3,380 / share, with a transaction value of Rp 103.65 billion. In the last week of trading, KAEF shares shot up 48.25% and in the last month it flew 183%.
Even in the last 6 months, the parent stock of PT Phapros Tbk (PEHA) has jumped 230%, tremendous.
Meanwhile, INAF shares also edged up 1.0% today at Rp 3,380 / share, the same level as KAEF. The difference is that INAF’s market capitalization is IDR 10.48 trillion, while KAEF is IDR 18.77 trillion.
INAF shares were traded for Rp 30.28 billion, in the last week its shares have jumped 48.25%, last month it flew 230%. In fact, in the last 6 months, the strengthening of INAF shares was even crazier, namely 305%. The PEHA’s shares were minus 0.26% at the level of Rp 1,950 / share.
The strengthening of pharmaceutical stocks, especially the KAE-INAF duo, occurred amid sentiment for the corona vaccine trial. President Joko Widodo (Jokowi) This Tuesday has conducted an implementation review the third stage clinical trial of the Covid-19 vaccine in Bandung, West Java. The clinical trial was held at the Faculty of Medicine, Padjadjaran University.
“Today I am present at the Faculty of Medicine UNPAD in Bandung, West Java, in order to see firsthand the implementation of the first injection. For immunization, 1,620 volunteers will be tested and we hope this 3rd clinical trial will be completed, God willing. in these six months, “said Jokowi.
“And we hope that in January we will be able to produce and at the same time, if the production is ready, vaccination will be given to all people in the country,” he continued.
According to Jokowi, production for vaccines is carried out by Bio Farma. For this August, approximately 100 million vaccines can be produced.
“But later on at the end of 2020 in December it will increase to 250 million vaccines. This means that this vaccine will be used for vaccination in the country,” said Jokowi.
(bag bag)
–
